Zevra Therapeutics (ZVRA) Net Equity Issued and Repurchased (2018 - 2024)

Zevra Therapeutics (ZVRA) posted Net Equity Issued and Repurchased of $63.4 million for Q3 2024, up 89353.52% on a QoQ basis from -$71000.0 in Q2 2024.

Zevra Therapeutics (ZVRA) Net Equity Issued and Repurchased (2018 - 2024) Analysis & Trends

Zevra Therapeutics' Net Equity Issued and Repurchased history runs 3 years deep, the most recent figure standing at $63.4 million for Q3 2024.

  • Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $63.4 million in Q3 2024, while the trailing twelve-month figure through Dec 2025 was $63.4 million (down 1.78% YoY) and the FY2024 annual result came in at $64.5 million, up 956.6% from the prior year.
  • Net Equity Issued and Repurchased was $63.4 million for Q3 2024 at Zevra Therapeutics, up from -$71000.0 in the prior quarter.
  • Across five years, Net Equity Issued and Repurchased topped out at $63.4 million in Q3 2024 and bottomed at -$71000.0 in Q2 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Zevra Therapeutics 239.71 Mn 39.10 Mn 34.32 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2024 63.37 Mn
Sep 30, 2024 63.37 Mn
Jun 30, 2024 -71,000.00
Jun 30, 2024 -71,000.00
Mar 31, 2024 1.22 Mn
Mar 31, 2024 1.22 Mn
Dec 31, 2023 6.11 Mn
Dec 31, 2023 6.11 Mn
Sep 30, 2018 836,000.00
Sep 30, 2018 836,000.00
Jun 30, 2018 1.19 Mn
Jun 30, 2018 1.19 Mn
Mar 31, 2018 2.80 Mn
Mar 31, 2018 2.80 Mn